[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study

por Baum, Richard P., Kluge, Andreas W., Kulkarni, Harshad, Schorr-Neufing, Ulrike, Niepsch, Karin, Bitterlich, Norman, van Echteld, Cees J.A.
Publicado 2016